Download PDF
Zeitschrift für Orthomolekulare Medizin 2011; 9(1): 17-21
DOI: 10.1055/s-0030-1270735
Praxistipps

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Seleneinsatz in der Onkologie

Ralph Mücke, Irenäus A. Adamietz, Ulrich Schäfer, Oliver Micke, Peter Holzhauer, Jens Büntzel
Further Information

Publication History

Publication Date:
15 March 2011 (online)

    Permissions and Reprints

Zusammenfassung

Selen ist ein essenzielles Spurenelement mit onkologischem Potenzial. Bei der krebspräventiven Wirkung besteht eine Abhängigkeit zum Selenspiegel im Blut. Der krebstherapeutische Effekt von Selen konnte inzwischen in einigen Studien im Rahmen der Therapie verschiedener Krebsarten gezeigt werden.

Schlüsselwörter

Selen - Selensupplementation - Onkologie - Prävention - Therapie

Literatur

  • 1 Asfour I A, Shazly S E, Fayek M H et al. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients.  Biol Trace Elem Res. 2006;  110 19-32
    CrossrefGoogle Scholar
  • 2 Asfour I A, Fayek M H, Raouf S et al. The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.  Biol Trace Elem Res. 2007;  120 1-10
    CrossrefGoogle Scholar
  • 3 Asfour I A, El-Tehewi M M, Ahmed M H et al. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.  Biol Trace Elem Res. 2009;  127 200-210
    CrossrefGoogle Scholar
  • 4 Beck M A, Nelson H K, Shi Q et al. Selenium deficiency increases the pathology of an influenza virus infection.  FASEB J. 2001;  15 1481-1483
    Google Scholar
  • 5 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults.  Arch Intern Med. 2008;  168 404-410
    CrossrefPubMedGoogle Scholar
  • 6 Blot W J, Li J Y, Taylor P R et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population.  J Natl Cancer Inst. 1993;  85 1483-1489
    CrossrefGoogle Scholar
  • 7 Brooks J D, Metter E J, Chan D W et al. Plasma selenium level before diagnosis and the risk of prostate cancer development.  J Urolog. 2001;  166 2034-2038
    Google Scholar
  • 8 Büntzel J, Micke O, Mücke R et al. Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer – redox data.  Trace Elem Electrolytes. 2005;  22 211-215
    Google Scholar
  • 9 Büntzel J, Glatzel M, Kisters K et al. Selenium as a radioprotector in head and neck cancer patients – first clinical results.  Trace Elem Electrolytes. 2006;  23 178-180
    Google Scholar
  • 10 Büntzel J, Micke O, Glatzel M et al. Evaluation of the effect of selenium on radiation-induced toxicities in head neck cancer.  J Clin Oncol. 2009;  27 (No 15 S) abstr. e20698
    Google Scholar
  • 11 Clark L C, Combs G F, Turnbull B W et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin.  J Am Med Assoc. 1996;  276 1957-1963
    CrossrefGoogle Scholar
  • 12 Duffield-Lillico A J, Dalkin B L, Reid M E et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.  BJU Int. 2003;  91 608-612
    CrossrefGoogle Scholar
  • 13 Fischer J L, Mihelc E M, Pollok K E, Smith M L. Chemotherapeutic selectivity conferred by selenium: a role for p 53-dependent DNA repair.  Mol Cancer Ther. 2007;  6 355-361
    CrossrefGoogle Scholar
  • 14 Fraunholz I, Jüling-Pohlit L, Böttcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors.  Trace Elem Electrolytes. 2001;  18 98-99
    Google Scholar
  • 15 Gudkov A V. Converting p 53 from a killer to a healer.  Nature Medicine. 2002;  8 1196-1198
    CrossrefGoogle Scholar
  • 16 Hatfield D L, Gladyshev V N. The outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology.  Mol Interv. 2009;  1 18-21
    Google Scholar
  • 17 Hu Y J, Chen Y, Zhang Y Q et al. The protective role of selenium on the toxicity of cisplatinum-contained chemotherapy regimen in cancer patients.  Biol Trace Elem Res. 1997;  56 331-341
    CrossrefGoogle Scholar
  • 18 Karp D D, Lee S J, Shaw Wright G L. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium supplementation in resected stage I non-small cell lung cancer.  J Clin Oncol. 2010;  28 abstr CRA7004
    Google Scholar
  • 19 Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer.  Int J Urol. 2006;  13 1180-1184
    CrossrefGoogle Scholar
  • 20 Knekt P, Aromaa A, Mantela J. Serum selenium and subsequent risk of cancer among Finnish men and woman.  J Natl Cancer Inst. 1990;  82 864-868
    CrossrefGoogle Scholar
  • 21 Last K W, Cornelius V, Delves T et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin's lymphoma.  J Clin Oncol. 2003;  21 2335-2341
    CrossrefGoogle Scholar
  • 22 Last K, Maharaj L, Perry J et al. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours.  Ann Oncol. 2006;  17 773-779
    CrossrefGoogle Scholar
  • 23 Lippmann S M, Klein E A, Goodman P J et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT).  JAMA. 2009;  301 39-51
    CrossrefGoogle Scholar
  • 24 Micke O, Bruns F, Glatzel M et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology.  EUJIM. 2009;  1 22-30
    Google Scholar
  • 25 Mücke R, Schomburg L, Glatzel M et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology.  Int J Radiation Oncology Biol Phys. 2010;  70 828-835
    Google Scholar
  • 26 Papp L V, Lu J, Holmgren A, Khanna K K. From selenium to selenoproteins: synthesis, identity, and their role in human health.  Antioxid Redox Signal. 2007;  9 775-806
    CrossrefGoogle Scholar
  • 27 Rayman M P. The importance of selenium to human health.  Lancet. 2000;  356 233-241
    CrossrefPubMedGoogle Scholar
  • 28 Schomburg L, Koehrle J. Selenium: benefits and risks.  MMW Fortschr Med. 2007;  149 34-36
    Google Scholar
  • 29 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.  Gynecol Oncol. 2004;  93 320-327
    CrossrefGoogle Scholar
  • 30 Vunta H, Davis F, Palempalli U D et al. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12, 14-prostaglandin J2 in macrophages.  J Biol Chem. 2007;  282 17964-17973
    CrossrefGoogle Scholar
  • 31 Weijl N I, Elsendoorn T J, Lentjes E G et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study.  Eur J Cancer. 2004;  40 1713-1723
    CrossrefGoogle Scholar
  • 32 Yu S Y, Mao B L, Xiao P et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study.  Biol Trace Elem Res. 1990;  24 105-108
    CrossrefGoogle Scholar
  • 33 Yu S Y, Zhu Y J, Li W G et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China.  Biol Trace Elem Res. 1991;  29 289-294
    CrossrefGoogle Scholar

Zoom Image
Dr. Ralph Mücke

Strahlentherapeutische Klinik
Klinikum Lippe GmbH

Rintelner Straße 85

32657 Lemgo

Email: ralph.muecke@klinikum-lippe.de

Dr. Ralph Mücke studierte in Rostock Medizin. Nachdem er seinen Facharzt für Strahlentherapie absolviert hatte, war er zunächst am Klinikum Weiden in der Oberpfalz als Oberarzt tätig. Danach praktizierte er in der Gemeinschaftspraxis für Radiologie und Strahlentherapie am St. Josef-Hospital in Wiesbaden, seit 2009 arbeitet er als Leitender Arzt der Strahlentherapeutischen Klinik am Klinikum Lippe GmbH.

Irenäus A. Adamietz

Klinik für Strahlentherapie und Radio-Onkologie Marienhospital Herne
Klinikum der Ruhr-Universität Bochum

Ulrich Schäfer

Strahlentherapeutische Klinik
Klinikum Lippe GmbH, Lemgo

Oliver Micke

Klinik für Strahlenheilkunde und Radioonkologie
Franziskus Hospital Bielefeld gGmbH

Peter Holzhauer

Veramed Klinik am Wendelstein in Brannenburg

Jens Büntzel

Klinik für Hals-, Nasen- und Ohrenheilkunde
Südharz-Krankenhaus Nordhausen gGmbH

      >